Foamix receives US patent on foam technology
Foamix, an Israeli developer of topical foams for dermatology and gynaecology, has been awarded a US Patent for its foam technology. The patent covers unique foam compositions suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections.
Foamix, an Israeli developer of topical foams for dermatology and gynaecology, has been awarded a US Patent for its foam technology. The patent covers unique foam compositions suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections.
Dr Dov Tamarkin, chief executive of Foamix, said: "The novelty of our foam technology platform is that it enables easy delivery of active agents to the inflicted site. Our foams are breakable - they are easily applied to the sensitive area of wounds and burns and they are absorbed readily into the treated area."
To date, Foamix holds five US patents covering its OilGel and topical foam technology. An additional 70 patents are pending.